With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market ...

The orders are granted after antisocial behaviour, violence and suspected drugs misuse. The walk-in support service in South Yorkshire aims to offer rapid support for substance addiction.

District Judge John Bates wrote the removals harm “everyday Americans, and most acutely, underprivileged Americans, seeking ...

Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98. The stock has a market cap of $11.83 billion, a P/E ratio of 35.52 and a beta of 0.33.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by improving, understanding, and advancing treatment.

Both Guggenheim's Yatin Suneja and Wainwright's Andrew Fein were more modest in their Neurocrine price target cuts, with the former shaving $2 off his target to $163 per share and the latter reducing ...

who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for ...

We recently compiled a list of the These 10 Firms Were Last Week's Worst Performers. In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the ...